Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Crystal S Denlinger

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Journal of Gastrointestinal Oncology|August 29, 2018
Concurrent chemoradiation for resected gall bladder cancers and cholangiocarcinomasMuhammad M Fareed, Lyudmila DeMora, Nestor F Esnaola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 2, 2026
Primary Care and Oncology Collaboration to Improve Patient OutcomesAaron Bailey, Wendeline Frederic, Ashley Orr, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2016
Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumorsLaura Q M Chow, David C Smith, Antoinette R Tan, et al.
Annals of Surgical Oncology|September 28, 2011
Significance of pathologic response to preoperative therapy in pancreatic cancerYun Shin Chun, Harry S Cooper, Steven J Cohen, et al.
Cancer Chemotherapy and Pharmacology|August 11, 2016
Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumorsDing Wang, Fadi Braiteh, James J Lee, et al.
Journal of Gastrointestinal Cancer|February 2, 2012
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research studyEfrat Dotan, Neal J Meropol, Barbara Burtness, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 15, 2023
Advancing More Equitable Care Through the Development of a Health Equity Report CardAlyssa A Schatz, Shonta Chambers, Gretchen C Wartman, et al.
Clinical Colorectal Cancer|October 24, 2018
Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous AppraisalJenica N Upshaw, Anne O'Neill, Joseph R Carver, et al.
Clinical Colorectal Cancer|September 5, 2016
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal AdenocarcinomasMichael Pishvaian, Michael A Morse, Jennifer McDevitt, et al.
Investigational New Drugs|June 21, 2015
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumorsMatthew Zibelman, Yu-Ning Wong, Karthik Devarajan, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Journal of Gastrointestinal Oncology|August 29, 2018
Concurrent chemoradiation for resected gall bladder cancers and cholangiocarcinomasMuhammad M Fareed, Lyudmila DeMora, Nestor F Esnaola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 2, 2026
Primary Care and Oncology Collaboration to Improve Patient OutcomesAaron Bailey, Wendeline Frederic, Ashley Orr, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2016
Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumorsLaura Q M Chow, David C Smith, Antoinette R Tan, et al.
Annals of Surgical Oncology|September 28, 2011
Significance of pathologic response to preoperative therapy in pancreatic cancerYun Shin Chun, Harry S Cooper, Steven J Cohen, et al.
Cancer Chemotherapy and Pharmacology|August 11, 2016
Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumorsDing Wang, Fadi Braiteh, James J Lee, et al.
Journal of Gastrointestinal Cancer|February 2, 2012
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research studyEfrat Dotan, Neal J Meropol, Barbara Burtness, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 15, 2023
Advancing More Equitable Care Through the Development of a Health Equity Report CardAlyssa A Schatz, Shonta Chambers, Gretchen C Wartman, et al.
Clinical Colorectal Cancer|October 24, 2018
Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous AppraisalJenica N Upshaw, Anne O'Neill, Joseph R Carver, et al.
Clinical Colorectal Cancer|September 5, 2016
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal AdenocarcinomasMichael Pishvaian, Michael A Morse, Jennifer McDevitt, et al.
Investigational New Drugs|June 21, 2015
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumorsMatthew Zibelman, Yu-Ning Wong, Karthik Devarajan, et al.
Pageof 10